Layer, Chiang, et al. Genome Biology
Exome Sequencing IDs Druggable BRAF Mutation in 47 HCL Patients
Since BRAF inhibitors such as Roche/Plexxicon's vemurafenib, or PLX 4032, are currently in clinical trials for melanoma patients, the authors think there could be a rapid transition of their findings to the clinic.
New to GenomeWeb? Register here quickly.